STOCK TITAN

Atara Biotherape Stock Price, News & Analysis

ATRA Nasdaq

Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.

Atara Biotherapeutics (NASDAQ: ATRA) is a leading innovator in cellular immunotherapy, developing transformative treatments for cancer and autoimmune diseases. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships.

Access timely updates on T-cell therapy advancements, including CAR T platform developments and collaboration progress with Memorial Sloan Kettering Cancer Center. Our curated collection features press releases about product candidates in oncology and autoimmune research, financial disclosures, and manufacturing updates.

Key content includes analysis of Phase 1-3 trial outcomes, FDA communications regarding allogeneic therapies, and licensing agreements supporting ATRA's pipeline development. Bookmark this page for direct access to primary source materials and objective reporting on the company's progress in addressing unmet medical needs through innovative immunotherapies.

Rhea-AI Summary

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) will release its Q1 2022 financial results on May 5, 2022, after market close. A live conference call will follow at 4:30 p.m. EDT to discuss the results and provide a corporate update. Atara is a leader in T-cell immunotherapy, utilizing its unique allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for cancer and autoimmune diseases. The company is advancing its pipeline, notably with tab-cel®, in Phase 3 clinical development for EBV+ PTLD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
-
Rhea-AI Summary

Atara Biotherapeutics, Inc. (NASDAQ: ATRA), a leader in T-cell immunotherapy, announced the grant of inducement awards to Brian Robinson, its new Senior Vice President of Global Medical Affairs. The awards include 73,449 restricted stock units and stock options to purchase 138,067 shares, with a performance-based component for an additional 15,689 shares. These awards are part of Atara’s 2018 Inducement Plan, effective April 18, 2022. All stock options have an exercise price of $7.73 per share, reflecting the closing price on the grant date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
-
Rhea-AI Summary

Atara Biotherapeutics has granted 37,538 restricted stock units to five newly hired employees as part of its 2018 Inducement Plan, approved by the Compensation Committee of its Board of Directors. The awards, announced on April 1, 2022, vest over four years, incentivizing employee retention. This initiative aligns with Nasdaq Listing Rule 5635(c)(4), highlighting Atara's commitment to employee engagement as it advances its T-cell immunotherapy platform to develop therapies for cancer and autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
none
Rhea-AI Summary

Atara Biotherapeutics (NASDAQ: ATRA) announces the appointment of Charlene Banard as Chief Technical Officer. Banard will oversee process science, quality, and manufacturing. CEO Pascal Touchon highlighted her extensive experience in advanced therapies, including CAR T. Previously, Banard served at Novartis and Shire, where she managed global quality and advanced product pipelines. Atara is known for its innovative T-cell immunotherapies targeting serious diseases, with its lead program in Phase 3 clinical development for EBV-driven conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
-
Rhea-AI Summary

Atara Biotherapeutics has announced the acquisition of its cell therapy manufacturing facility in Thousand Oaks, California, by FUJIFILM Diosynth Biotechnologies for USD 100 million. This strategic move, coupled with a long-term supply agreement, aims to enhance Atara's capacity for clinical and commercial-stage allogeneic cell therapies, including promising candidates like tabelecleucel and ATA188 for multiple sclerosis. The agreement is expected to reduce Atara's operating expenses and provide financial support into Q4 2023, aiding in the development of innovative therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.59%
Tags
partnership acquisition
-
Rhea-AI Summary

Eikon Therapeutics has appointed Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer, effective July 11, 2022. Dr. Baynes, a distinguished oncologist with extensive experience, previously held senior roles at Merck and Amgen, contributing to the development of significant drugs like Keytruda. He will lead the company's clinical research and development, leveraging Eikon's advanced technologies in drug discovery. This appointment aims to strengthen Eikon's ability to deliver innovative therapies for serious illnesses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.3%
Tags
management
Rhea-AI Summary

Atara Biotherapeutics (NASDAQ: ATRA) will host an EBV and MS Day on March 22, 2022, from 4:00 p.m. EDT. CEO Dr. Pascal Touchon and the management team will discuss the role of Epstein-Barr virus (EBV) in multiple sclerosis (MS), the development of ATA188, and review Phase 1 clinical data. Renowned experts like Mark Freedman and Lawrence Steinman will provide insights. The event includes a conference call for analysts and investors, with a live webcast available on atarabio.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.58%
Tags
conferences
-
Rhea-AI Summary

Atara Biotherapeutics (NASDAQ: ATRA) reported granting 45,040 restricted stock units and 39,978 stock options to newly hired employees. These awards were approved by Atara’s Compensation Committee and are part of the 2018 Inducement Plan. The restricted stock units will vest over four years, with 25% vesting on the first anniversary. The stock options have a ten-year term and an exercise price of $10.21 per share. This announcement aligns with Nasdaq Listing Rule 5635(c)(4) requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
none
-
Rhea-AI Summary

Atara Biotherapeutics (NASDAQ: ATRA) will have its CEO, Pascal Touchon, participate in a cell therapy panel at the Cowen 42nd Annual Virtual Healthcare Conference on March 9, 2022, at 9:10 a.m. EST. The event emphasizes Atara's leadership in T-cell immunotherapy, particularly leveraging its allogeneic Epstein-Barr virus (EBV) platform for cancer and autoimmune disease treatments. A live webcast will be available on their website, with an archived replay accessible for 30 days post-presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
conferences
Rhea-AI Summary

Atara Biotherapeutics (Nasdaq: ATRA) announced that a U.S. BLA submission for tab-cel is not expected in Q2 2022 due to further FDA alignment needed. However, the EU approval is on track for Q4 2022. The company reported a Q4 2021 net loss of $93.3 million and a total operating expense increase of 18% compared to the previous year. Significant advances were made in the development of ATA188 for progressive multiple sclerosis, which has received Fast Track designation from the FDA. Atara also entered a $100 million strategic manufacturing partnership with Fujifilm.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.54%
Tags

FAQ

What is the current stock price of Atara Biotherape (ATRA)?

The current stock price of Atara Biotherape (ATRA) is $8.25 as of July 2, 2025.

What is the market cap of Atara Biotherape (ATRA)?

The market cap of Atara Biotherape (ATRA) is approximately 47.8M.
Atara Biotherape

Nasdaq:ATRA

ATRA Rankings

ATRA Stock Data

47.81M
5.30M
21.98%
50.5%
12.2%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
THOUSAND OAKS